PJ Anand
Founder and CEO
Alcyone Life Sciences

PJ Anand is the founder of Alcyone Lifesciences and serves a...

Mirena Bagur founded the company in 2005. During almost two decades
of marketing and communications experience, Mirena ...

Nancy Briefs

Ms. Briefs' background includes 30+ years in the medical device industry.

Pravin Chaturvedi
Chairman & CEO
IndUS Pharmaceuticals,

Pravin Chaturvedi has over 18 years of pharmac...

John Conley
Launchpad Venture Group

Bill Contente
Launchpad Venture Group

Bio: BS Economics, Wharton School, Universi...

James E. Dawson is a partner in the Business Department and a member of
the firm's Life Sciences group. He practices in...

Ben Gardner
Founder and President
Linkwell Health

Adam Ghander

Ben founded Linkwell Health in...

Launched and managed an injection molding company that manufactured
close-tolerance custom plastic components for use i...

Dave Greenwald
Co-Founder and Managing
Relay Technology

Dr. Greenwald is a co-founder of Relay Tec...

Rana Gupta has spent the last 12 years investing in and developing novel
technologies. His passion for entrepreneurship...

Jeremy Halpern
Nutter McClennen & Fish

Jeremy Halpern, is a Partner, and the Director of Business Development,...

Konstantin Linnik is a partner in Nutter’s Intellectual Property Department.
He works with biotech, pharma and other li...

Semprus BioSciences co-founder David L. Lucchino served as Chief
Executive Officer and President of Semprus BioSciences...

Corey McCann
MPM Capital

Nandini Murthy
Principal and Founder
ENEM Consulting LLC

Dr. Corey M M...

Vinit Nijhawan
Managing Director,
Technology Development
Boston University

Dimitri Racklin
Launchpad Venture Group


Cheryl Richardson
Launchpad Venture Group

Cheryl Richardson is the New York Times bestselling author of several
books ...

Praveen Tailam
Managing Director
TiE Angels Boston

As a managing director Praveen overseas the operation of...

Leslie Williams

Leslie Williams has more than 20 years of industry experience in
healthcare, ma...

Dr. Jill Wittels is CEO of Sostenuto Strategic Advisors and a Founding
Partner and Chief Technology Officer of Terra Pr...

Upcoming SlideShare
Loading in …5

Life Science Fast Track Faculty and Mentor Directory


Published on

Are you a physician, innovator, or entrepreneur with a commercial idea and ready to make it a fundable company? Join us for this full-day program to understand today’s unique challenges for life science, med device, and healthcare entrepreneurs starting companies and raising capital. Learn from and meet some of the leading life science investors, entrepreneurs, and early-stage experts in New England.

Building on the success of The Capital Network’s annual Fast Track Boot Camp for Entrepreneurs, this Life Science Fast Track is an intensive, interactive full-day seminar designed to provide entrepreneurs and innovators an in-depth understanding of what it takes to raise early stage capital for a life science startup.

Published in: Business, Technology
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Life Science Fast Track Faculty and Mentor Directory

  1. 1.   PJ Anand Founder and CEO Alcyone Life Sciences @AlcyoneLS PJ Anand is the founder of Alcyone Lifesciences and serves as its President and CEO, with over 20 years of experience in life science industry. Prior to founding Alcyone Lifesciences, PJ was a founding executive of Arsenal Medical, Inc., the first collaborative enterprise between Drs. George Whitesides, Prof. Harvard University (founder of Genzyme, Geltex, Theravance) and Bob Langer, Institute Prof. MIT (founder Momemta, MicroChip, Pervasis). As Executive Vice President of Corporate Development, PJ was responsible for leading Arsenal's corporate strategy and business development activities including technology in-licensing, out-licensing and strategic alliances. In preparation for this role, PJ served as the Company's Vice President of Business and Commercial Development and working closely with Arsenal's technology visionaries, operational team and founding scientists played a critical role in creation of Arsenal's platform and product portfolio as well as executing on key strategic alliance transactions. Prior to joining Arsenal in 2005, PJ served as Vice President & General Manager of Spire Biomedical, Inc., a division of Spire Corporation (NASDAQ: SPIR), where he was responsible for establishing a medical products business unit. While at Spire, PJ was responsible for R&D, sales & marketing and business transactions. In addition, PJ was chiefly responsible for identifying and in-licensing the seminal technology for the company as well as executing major transactions with medical device companies that resulted in several million dollars of non-dilutive revenue for the company. PJ has also served as head of business development for Toxikon Corporation, a preclinical CRO based out of Massachusetts. PJ Anand has a bachelors degree and a masters level education in Biochemistry and has several patent pending inventions to his credit. Rich Anders Managing Director MassMed Angels Richard Anders is a seasoned entrepreneur who has had careers in computers, publishing, and consulting, and has a strong personal focus on life sciences and life science investing. He is the managing director of Rubin/Anders, a leading placement agency for scientific experts in major litigations. Previously, he founded Jurisoft, which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital Industry, and was a founding trustee of the Massachusetts Interactive Media Council. Richard is a trustee of the Boston Museum of Science, a former trustee of the Boston Biomedical Research Institute and an overseer of the Gardner Museum. He is a member of the Institutional Review Board at the Dana Farber Cancer Center, which reviews clinical trials for the hospital. He founded the angel group Launchpad and founded and currently runs MA Medical Angels (MA2), one of the country's leading angel groups focused exclusively on life sciences. He currently serves on the board of Bliss Healthcare, is a board observer at Avaxia Biologics, and served on the board of Quosa, Inc., which was acquired by Elsevier Publishing. Richard teaches medical device entrepreneurship at the Harvard/MIT HST program. He is a graduate Summa Cum Laude in Mathematics from Harvard and holds a J.D. from Harvard Law School. 1  
  2. 2.   Mirena Bagur founded the company in 2005. During almost two decades of marketing and communications experience, Mirena has counseled a wide variety of technology-inspired companies. In addition to executing marketing programs for clients, Mirena is the Associate Course Director of the joint Harvard-MIT Division of Health, Sciences, and Technology course HST.921 "Information Technology in the Heath Care System of the Future". Mirena Bagur President CONTeXO Group @MirenaBagur Prior to this, Mirena was a senior vice president at Weber Shandwick, a leading global communications agency. She collaborated with emerging and enterprise companies to conceive and execute strategic marketing and PR programs. Mirena’s capabilities to grasp not only clients’ brand issues, but also understand the challenges associated with educating the influencers on the adoption of complex concepts and technologies in business environments, translated into leading roles in numerous technology and healthcare accounts. She led teams that thoughtfully coordinated marketing programs with strategic partners, led communications campaigns for industry analyst firms, and was chosen to lead national-level initiatives designed to elevate Weber Shandwick’s brand and to increase visibility in new markets (start-ups and healthcare businesses, boomers’ market) resulting in numerous referrals and revenue increase. Prior to Weber Shandwick, Mirena worked at T-Catalyst, a public affairs agency and Nathan Tyler Productions, a producer of business videos including “in Search of Excellence.” Prior to that, Mirena founded a branch of the American Institute for Foreign Studies, the "Camp America" student exchange program in former Yugoslavia when she developed and implemented business and marketing plans, and procured approval of the program by government. Mirena holds a bachelor’s degree in international trade and marketing from the University of Zagreb, Croatia, and has completed a strategic business leadership program at Columbia University. 2  
  3. 3.   Nancy Briefs CEO InfoBionic @nancybriefs Ms. Briefs' background includes 30+ years in the medical device industry. She is a serial entrepreneur and has been an integral team member responsible for successfully developing and commercializing innovative paradigm shifting technologies with five (5) prior med-tech startups. Having raised over $200M in venture capital and four successful liquidity events (including an IPO with Goldman Sachs) she has proven the ability to lead teams from concept thru commercialization and value creation. She was awarded: with the Ernst & Young (EOY) New England Entrepreneur of the Year Award for Emerging Companies in 2003; received the "Spirit Award" in 2009 from NH Biotech Council and in 2010 was honored with a "Leadership & Inspiration: Award from WEST (Women Entrepreneurs in Science and Technology). She currently serves on the Boards of: MDMA (Medical Device and Manufacturers Association), CardiAQ Valve Technologies, Apama Medical and InfoBionic. An entrepreneur inventor she is listed on seven issued and two pending US patents. Nancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia University. A notable and inspiring public speaker, Ms. Briefs has spoken at the MIT Enterprise Forum, Harvard Medical School, Tuck School at Dartmouth College, NH Women’s Leadership Conference, Smith College, WEST, MassMEDIC, MIT Sloan School, Venture One, MDMA, MedTech Insight, OneMedForum and other numerous industry events. Lauren Celano CEO Propel Careers @Propel_Careers Lauren Celano is Co-founder and CEO of Propel Careers and has nearly a decade of experience working with emerging drug discovery & development biotechnology companies. Prior to Propel Careers, she was a senior account manager for SNBL USA where she worked with emerging biotech companies in Europe and the US to help characterize and advance their drug molecules. Prior to SNBL USA, she held business development positions with Aptuit and Quintiles, where she focused onIND enabling studies to advance therapeutics from discovery into the clinic. At Absorption Systems, Lauren held positions as a marketing manager and account manager managing clients in the northeastern United States. She has a B.S. in Biochemistry and Molecular Biology from Gettysburg College and an MBA with a focus in the health sector and entrepreneurship from Boston University. Lauren is on the membership committee of the North Shore Technology Council and the Healthcare Businesswomen’s Association and on the programming committee of The Capital Network. 3  
  4. 4.   Pravin Chaturvedi Chairman & CEO IndUS Pharmaceuticals, Inc. @tieboston Pravin Chaturvedi has over 18 years of pharmaceutical industry experience and has been associated with the discovery and development of several novel drugs for the treatment of a variety of diseases. Over his career, Dr. Chaturvedi has been a part of the discovery, development and marketing of five new drugs that are on the market (globally) and has more than 10 new drugs undergoing clinical evaluation at this time at his previous companies. Currently Dr. Chaturvedi is the founding Chairman & CEO of IndUS Pharmaceuticals, Inc., an emerging pharmaceutical company, headquartered in the Boston area (with a subsidiary Sindu Pharmaceuticals Pvt. Ltd., in Hyderabad, India). IndUS Pharmaceuticals is focused on the discovery and development of novel small molecule drugs for the treatment of cancer, diabetes and infectious diseases. Prior to founding IndUS Pharmaceuticals, Dr. Chaturvedi was the founding President & CEO of Scion Pharmaceuticals, a Boston-based biotechnology company focused on the discovery and development of new drugs targeting ion channels for the treatment of central nervous system (CNS), cardiovascular (CV) and urological disorders. Under his leadership, Scion successfully recruited a very experienced management team that achieved key scientific and business milestones and raised venture capital to support its R&D operations. Prior to Scion, Dr. Chaturvedi, spent several years at Vertex Pharmaceuticals, where as the Head of Lead Evaluation and he had oversight of several therapeutic programs from early discovery through clinical proof-of-concept studies (phase IIA). During his tenure at Vertex, he played a key role in the discovery and development of several therapeutic agents for immunosuppressive, anti-inflammatory, anti-viral, oncology and neuroscience indications. Prior to Vertex, Dr. Chaturvedi was in the preclinical group at Alkermes, where he participated in CNS and oncology product development through novel strategies for crossing the blood-brain-barrier (BBB). Prior to Alkermes, he was in the Product Development group at Parke-Davis/Warner-Lambert Company, where he worked on the development of new drugs for the treatment of oncology, epilepsy, pain and cognition. Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor's in Pharmacy from the University of Bombay. Yumin Choi Partner HLM Venture Partners @YuminVC Yumin is currently a Director of Vets First Choice and is a board observer at Institute for Health Metrics (IHM), Nordic Consulting, and TYRX. Yumin is a director to The Capital Network, a non-profit focused on educating entrepreneurs around topics of fundraising and finance. He previously was chair of the New England Venture Network (NEVN), the largest young Venture Capital organization in New England. Yumin is co-chair of the Boston Symphony Orchestra Venture Capital and Private Equity committee and is on Boston University’s Coulter Foundation Oversight Committee. Prior to HLM, Yumin was with Angel Healthcare Investors, a health care focused early stage investment group, ZweigWhite’s Financial Advisory Services and Mergers & Acquisitions Group and was co-founder and CEO of CY Digital. He is also a mentor in health care focused startup accelerators, Blueprint Health and Healthbox, and is an active angel investor. Yumin received a BS from Babson College. 4  
  5. 5.   John Conley Launchpad Venture Group Bill Contente Launchpad Venture Group Bio: BS Economics, Wharton School, University of Pennsylvania. MBA, Yale School of Management. Manager, Bain and Company. 10 years with Biogen: business development, marketing, sales, finance, project management. Co-founder, first employee, VP Strategy and Finance of Alnylam Pharmaceuticals Inc. through to its IPO. VP Business Development, Transkaryotic Therapies Inc. Advisor with JSB Partners LP (life science deal broker). Partner at Gilliam Capital LLC, pursuing life science start ups and venture financing. 2014: Advanced Leadership Fellow at Harvard University Bill Contente is a corporate lawyer and former Managing Partner at Gesmer Updegrove LLP. He represents a wide range of emerging companies, including companies focused on e-commerce, SaaS, computer hardware and software, medical devices, systems integration and other services, angel investment and consulting. He has represented his clients through hundreds of financing deals, including angel deals, venture capital investments, private equity investments, bridge financings and bank financings. He also has extensive experience in corporate exit transactions, including mergers, acquisitions, stock deals and asset deals. Mr. Contente is Chairman of the Board of Launchpad Venture Group, one of the nation’s top 5 angel investment groups. He has served as a director and member of the Executive Committee of the Coolidge Corner Theatre Foundation (2006 – 2012), Chairman of the Board of Lena Park Community Development Corporation (1997 – 2002), Co-chair of the High Technology Practice Group of the Massachusetts Bar Association (1994 – 1999) and an Arbitrator for the National Futures Association (1989 – present). 5  
  6. 6.   James E. Dawson is a partner in the Business Department and a member of the firm's Life Sciences group. He practices in the areas of corporate and securities law, including mergers and acquisitions, public offerings, private placements and investment adviser representation. He represents life sciences companies, including biotech and medical device companies, and life science venture funds, as well as emerging and high tech companies. Jim Dawson Partner Nutter McClennen & Fish Jim has handled more than 100 mergers and acquisitions of both public and private buyers and sellers. He represents public companies, handling all facets of securities law issues, including compliance with SarbanesOxley. Jim is a former co-chair of the Boston Bar Association’s Securities Law Committee and has been a frequent lecturer at Massachusetts Continuing Legal Education. He also represents companies based in Europe and Asia doing business in the U.S. Jim is a member of the American, Massachusetts and Boston Bar Associations. Eric J. Evans has nearly thirty years of experience in the life sciences industry, as executive, consultant and investor. Since 2010 he has been active as an investor and interim CEO for a variety of early-stage and emerging companies in therapeutics, devices and diagnostics. Eric Evans MassMed Angels Targeted Cell Therapeutics From 2007 to 2010, he was Chief Executive Officer of Targeted Cell Therapies, a Worcester-based biotechnology company developing gene therapies for various inherited disorders. While there, he was responsible for overseeing drug discovery and development, business intelligence, business development & licensing, competitive analysis, strategy development, corporate financing, staffing and administration, and alliances with other pharmaceutical companies. He took the company from founding by its scientists through several key milestones, culminating in the negotiation of an exit to a big international pharma company. Previously, Mr. Evans had advised nearly all of the world’s largest pharmaceutical companies on issues of growth, strategy, market assessment and business development, while with the Boston Consulting Group and then for nearly fifteen years as president of Growth Analytics Inc., a strategy boutique based in the U.S. and Europe. He has also worked extensively in the related industries of medical devices and diagnostics. He began his career at Procter & Gamble, in brand management, an experience that continues to inform his work in consumer health. He has been a policy adviser to various candidates for public office, and has taught as an adjunct professor on the faculty of County College of Morris. Mr. Evans holds a B.S. in biomedical Physics from Brown University and an M.B.A. in Finance and Public Policy (double major) from the Wharton School, University of Pennsylvania. 6  
  7. 7.   Ben Gardner Founder and President Linkwell Health @LinkwellHealth Adam Ghander Partner Ben founded Linkwell Health in 2007 with the mission of developing simple, meaningful ways to engage and empower consumers to promote healthier lifestyles. Ben’s 20+ years of experience spans both the healthcare and marketing services sectors, working primarily in start-up and early stage businesses. Ben was Vice President of Sales for 10 years at Imagitas, a marketing services company reaching the new mover market through an exclusive relationship with the U.S. Postal Service. Ben also led ParentSource (a successful couponing and sampling partnership with McDonalds) and DriverSource (a direct marketing program in partnership with state DMVs). Ben’s earlier career was focused on healthcare, working for companies including Stryker Medical (medical devices) and HPR (clinical software). Ben is a graduate of Bentley University with a BA in Marketing. Adam B. Ghander focuses his corporate finance and securities practice on private equity, venture capital, and emerging companies representation; mergers and acquisitions; and securities regulations. He represents clients in a wide variety of industries, including banking and financial services, telecommunications, social networking, manufacturing and professional sports. Adam previously served as in-house counsel for a publicly-traded manufacturing and technology company. Prior to his in-house experience, he spent many years as a corporate attorney at the Boston office of an international law firm. Adam lectures frequently on corporate finance and teaches at the Boston University School of Management. Nutter McClennen & Fish @NutterLaw 7  
  8. 8.   Launched and managed an injection molding company that manufactured close-tolerance custom plastic components for use in technicallydemanding applications. The company was self-financed and profitable from the first year of operation.   Mike Gordon Launchpad Venture Group Launched and managed a very profitable company that developed and manufactured products that controlled static electricity for the microelectronics industry (25 - 30% EBITDA). Sold to a public British company. Founded two business networks, one face-to-face and one in virtual space that bring entrepreneurs together with capital providers. Founded a private management consulting firm for CEOs seeking funding, growth, global competitive advantage and corporate revitalization. Adjunct Lecturer: Babson College, Harvard Extension School, ISM, France, many others. Recipient of the 2009 Teaching Excellence Award for the entire International Region from the Association of Collegiate Business Schools and Programs (ACBSP) Curriculum and Editorial Review Boards: International School of Management; Paris Managed departments of engineers and technicians that had responsibilities for developing state-of-the-art chemical and plastic manufacturing processes. Wrote book entitled: “Entrepreneurship 101: How to Turn Your Idea Into a Money Machine,” John Wiley & Sons, Inc., 2nd Edition, 2010 (Trump University Series) Many patents and publications Many national/international speaking & teaching engagements: DBA, MBA, Exec. Ed Discovered a unique chemical reaction during PhD thesis research. Reviewed over 1500 Executive Summaries / Business Plans Developed a unique predictive model for the nine entrepreneurial thriving forces. Member, Launchpad Venture Group, one of the 5 largest angel groups in the USA . 8  
  9. 9.   Dave Greenwald Co-Founder and Managing Director Relay Technology Management Dr. Greenwald is a co-founder of Relay Technology Management, Inc. and currently serves as Managing Director. Dr. Greenwald was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD. Dr. Greenwald worked with the Food and Drug Administration (FDA) on 510(k) applications for diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute (HHMI) research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park. Dr. Greenwald was awarded an NIH Ruth L. Kirschstein National Research Service Award (NRSA) towards his Ph.D. research dissertation on gene therapy for Retinitis Pigmentosa. Dr. Greenwald is an active Licensing Executive Society member, and serves on the Board of Directors for Piers Park Sailing Center in Boston, MA. Dr. Greenwald focuses on infectious diseases, cancer and genetics and enjoys sailing in Boston harbor. Dr. Greenwald publishes his perspectives on the entrepreneurism and the innovation economy on his personal blog. 9  
  10. 10.   Rana Gupta has spent the last 12 years investing in and developing novel technologies. His passion for entrepreneurship is concentrated in entrepreneurial finance and technology development. Rana Gupta Boston University Most recently, Mr Gupta was CEO of HistoRx, a cancer diagnostics company and Yale University spin-out. He ran HistoRx for six years until selling the company to Novartis AG in September 2012. Previous to HistoRx, Mr Gupta was Managing Director at Navigator Technology Ventures (NTV). NTV was an early stage technology venture capital firm spun out of Draper Laboratory and based in Cambridge, MA. NTV’s investments were in multiple industry sectors including materials, software, medical devices and media. Six of NTV’s investments were laboratory or university spin-outs. For the last eight years, Mr Gupta has been teaching in BU’s entrepreneurship program in the areas of entrepreneurial finance and technology development. Prior to his position with NTV, Mr Gupta was Product Manager for Global Services with yet2.com, a B2B marketplace for technology transfer. Before yet2.com, Mr Gupta founded IndoSine U.S. Link, Ltd., a business development company that helped clients to expand international businesses between India, China, and the U.S. While running IndoSine, Mr Gupta co-founded a wireless software company, International Solutions, a digital signal processing software company, for which he served as Vice President of Sales and Marketing. Previous to IndoSine, he served as Manager, PRC Investment Strategy for Zeneca Pharmaceuticals in Beijing, China. At Zeneca, Mr Gupta was responsible for the China manufacturing strategy, for which he secured a $22M investment from the Board of Directors. Previous to Zeneca, Mr Gupta was a senior consultant at Arthur D Little, a technology consultancy. Stationed primarily in Cambridge, MA, Mr Gupta also served as a member of the start-up team for Arthur D Little’s Bangalore, India office. He holds an MBA in Finance and International Business from New York University's Stern School of Business, an MS in Operations Research from Stanford University, and a BA in Mathematics from Earlham College. 10  
  11. 11.   Jeremy Halpern Partner Nutter McClennen & Fish Jeremy Halpern, is a Partner, and the Director of Business Development, Emerging Companies Group, at Nutter McClennen & Fish LLP. As a former entrepreneur in mobile and entertainment, Jeremy concentrates on connecting with and supporting the Entrepreneurial Ecosystem in New England, working with current entrepreneurs, angel investors, venture capitalists and corporate strategic partners. In addition to his work with TCN, Jeremy is an angel investor, and serves on the Boards of MassVentures, a MicroVC firm and Pintley, a next generation marketing company for the brewing industry. Jeremy is a member of or participates at Launchpad Venture Group, Boston Harbor Angels, Golden Seeds, TiEAngels, MassChallenge, Web Innovators Group, MassTLC, Mobile Mondays and other area industry groups. He is a graduate of UC Berkeley and the UCLA School of Law. @startupboston Paul is a longtime life sciences executive with a proven track record in launching successful startup businesses and leading Fortune 500 organizations. He has extensive experience in the laser and medical device industries, including managing manufacturing for Summit Technology, Inc., a leading developer of the LASIK procedure and other laser eye correction procedures. Paul Hartung President and CEO Cognoptix Mike Koeris Founder and COO Sample6 Technologies Prior to Cognoptix, Paul was Vice President of Operations at Winphoria Networks, a successful mobile communications startup acquired by Motorola. Before that he was Senior Director at 3Com Corporation, where he was involved in a number of mergers and acquisitions, and directed global operations and new product introductions. At Trumpf, he developed high power automated laser systems for industrial applications. As Director of R&D at Laser Fare Ltd., he developed new laser processing techniques for the medical device industry and other applications. Paul started his career as an Advanced Manufacturing Engineer at General Electric Company. He graduated from MIT with an MS Degree in Mechanical Engineering. He received the FW Taylor Award of the CIRP for his research. Micah is a co-founder and CEO of Sample6 Technologies. Prior to Sample6, Micah co-founded Brontes Technologies, Inc. in 2003 and served as General Manager of the business after its acquisition by 3M Corp in 2006. Brontes technology was a handheld 3D imaging system that replaced traditional paste-based dental impressions. Prior to Brontes, Micah co-founded SimplyDone Business Solutions/Handshake.com, in which he raised over $20,000,000 in financing from venture and strategic investors. Micah received his B.S. degree from Cornell University and his MBA from Harvard Business School. Micah is also on the Board of Advisors for Cornell's Entrepreneurship Program, and is a Founder Partner to the Founder Collective, a Boston/NYC based seed stage venture fund. 11  
  12. 12.   Konstantin Linnik is a partner in Nutter’s Intellectual Property Department. He works with biotech, pharma and other life sciences companies on various matters involving intellectual property. Examples include: strategic counseling, building and leveraging patent portfolios, competitive analysis, product design and development, licensing and negotiations, due diligence and IP audits, and patent enforcement and litigation. Konstantin Linnik Partner Nutter McClennen & Fish @LifeSciIP Before joining Nutter Konstantin was Senior Corporate Counsel at Pfizer, where he was lead patent counsel for Pfizer research units located in Cambridge, Massachusetts; Düsseldorf, Germany; and Ottawa, Canada. Prior to Pfizer, he had extensive experience representing many pharma and biotech companies as their external counsel. Active in the Boston legal community, Konstantin currently chairs the Biotechnology Committee of the Boston Patent Law Association and serves as co-chair of the Massachusetts Biotechnology Council’s Legal & Regulatory committee. In addition, he serves on the board of directors of Seeding Labs. He also frequently speaks or lectures on IP-related topics such as: IP strategy; the role of IP counsel in business transactions; duty of disclosure; claim drafting; intellectual property due diligence; and IP licensing. Konstantin is an adjunct professor at Suffolk University Law School. He also serves on Nutter's Diversity and Inclusion Committee. 12  
  13. 13.   Semprus BioSciences co-founder David L. Lucchino served as Chief Executive Officer and President of Semprus BioSciences until its acquisition by Teleflex Medical, Inc. (NYSE: TFX) for $80 million. He then served as a Vice President executing the post M&A integration plan for eighteen months. David Lucchino Co-Founder Semprus BioSciences @SemprusBio Mr. Lucchino co-founded Semprus BioSciences while attending the Massachusetts Institute of Technology where he earned an MBA as an Alfred P. Sloan Fellow. He led an MIT team to first place at entrepreneurial competitions at MIT, Harvard and Oxford universities’ by beating more than 300 teams collectively. Under Mr. Lucchino’s stewardship, Semprus BioSciences grew from two to 45 employees, secured $28.5 million in venture capital financing, $5.4 million in federal funding and received regulatory approval from the FDA and the European Union for their first product. Mr. Lucchino is a member of the Board of Directors of the Massachusetts Biotechnology Council, the leading not-for-profit organization that supports the region’s biotechnology industry. He is a Trustee of Mt. Auburn Hospital, a Harvard Medical School teaching facility and also serves on the Audit Committee for CareGroup: the parent organization of Mt. Auburn, Beth Israel Deaconess Medical Center and The New England Baptist Hospital. Mr. Lucchino was a member of the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the national trade association representing the U.S. medical device industry from 2010 to 2013. Mr. Lucchino began his career as a technology marketing executive. He also earned a Master of Science degree from Syracuse University and a Bachelor of Arts degree from Denison University. Outside the office, Mr. Lucchino is active with the National Outdoor Leadership School (NOLS), where he was part of an expedition that climbed Alaska’s Mt. McKinley, North America's tallest mountain, and spent 95 days living in the Rocky Mountains as part of a leadership training program. He most recently rafted down Idaho’s “River of No Return,” the Salmon River, with NOLS. Mr. Lucchino has also participated as part of the Boston Red Sox’s “Team 9” in the annual Pan Mass Challenge, the two-day bike ride that raises funds for adult and pediatric cancer care and research at Dana-Farber Cancer Institute. 13  
  14. 14.   Corey McCann Principal MPM Capital @MPMCapital Nandini Murthy Principal and Founder ENEM Consulting LLC Dr. Corey M McCann joins MPM's Boston office as a Principal. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. In addition, he was a leader of McKinsey's Central Nervous System (CNS) expertise group, advising clients across the healthcare value chain. Dr. McCann brings investment experience to MPM. He was previously an Associate with RiverVest Venture Partners where he performed diligence on early stage investments and he was also a Market Analyst for NeuroInsights, covering advances in brain related technologies. He is a founding member of Alcyone Lifesciences, a startup focused on developing treatments for chronic neurologic conditions. Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his Ph.D., he studied the molecular biology of synapses at Harvard University and Washington University in St Louis. He was also a researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology. Ms. Murthy is Principal and Founder of ENEM Consulting LLC, a regulatory consulting firm based in MA. As a Consultant, Ms. Murthy has worked with clients in industry and academia, on novel diagnostic and therapeutic products, including cardiovascular, neurological, radiological, imaging, urological and oncology devices. Ms. Murthy has developed regulatory strategy, represented clients at FDA meetings and authored FDA submissions. She has also led worldwide regulatory projects, including product launch in the EU, Japanese and South American markets. In addition to her core expertise in regulatory affairs, Ms. Murthy has designed and executed clinical trials and established quality systems to ISO and FDA Quality System requirements. This complementary work experience enables Ms. Murthy to provide the kind of comprehensive regulatory support crucial to novel, early stage ventures, aligning the engineering and clinical support documentation with overall regulatory strategy. Prior to establishing ENEM Consulting LLC in 2007, Ms. Murthy held senior management positions at InfraReDx, Cyberkinetics Neurotechnology Systems, Thermo Cardiosystems and Hologic. Ms. Murthy holds a M.S. from UMass-Boston. 14  
  15. 15.   Vinit Nijhawan Managing Director, Technology Development Boston University Dimitri Racklin Launchpad Venture Group Detlef Rethage Launchpad Venture Group Vinit Nijhawan has over 25 years experience building five startups: as CEO of three, four were acquired, and the fifth has grown to over 300 people. Recently, Vinit was Venture Partner at Key Venture Partners and over two years sourced over 200 deals and made one investment which was acquired for $430M. Vinit is an advisor and board member to several technology startups and was a Mass High Tech All-Star in 2005. Vinit has participated in over 120 panel discussions and paper presentations, and is a Board of Trustee of TiE Global, a non-profit that fosters entrepreneurship globally. Vinit is Managing Director, Office of Technology Development, and Director of Enterprise Programs at ITEC (Institute of Technology, Entrepreneurship & Commercialization) at Boston University. Vinit also teaches an MBA course on Entrepreneurship at BU. Vinit earned a B.A.Sc in electrical engineering from the University of Waterloo in Ontario, Canada. Dimitri Racklin is the founder and principal of RacklinLaw LLC, a boutique corporate law practice he started at the beginning of 2013, focusing on emerging growth and other privately held companies; venture capital and private equity; M&A; corporate partnering, strategic alliances and licensing/technology transactions; project development/finance; and general corporate work. Prior to starting RacklinLaw, Dimitri was a corporate partner at WilmerHale (formerly Hale and Dorr) since 1995, where his practice followed a similar focus and included clients in biotech/pharma, health care, technology and telecommunications, energy and power, financial services, gaming, professional services, food and beverage and other industries. In 2007, Dimitri joined Fidelity as a Senior Vice President and Deputy General Counsel (supporting Devonshire Investors, Fidelity's private equity arm), returning to WilmerHale in 2008. Prior to Hale and Dorr, Dimitri worked in Washington, DC and Moscow, Russian Federation offices of Vinson & Elkins and Fried, Frank, Harris, Shriver & Jacobson, both major national law firms. Dimitri holds a B.A. from Yale University and a J.D. from Harvard Law School, and is an active angel investor. As team leader, developed organizations, transformed cultures and improved profitability of drug development service companies, CRO's / CMO's and fine chemical businesses. Experienced with small and large national/international organizations in General Management, Strategic Development and M&A in the USA, Germany and Italy. Expertise: Leadership. Build teams/organizations. Develop and implement strategies. Improve revenue, profitability and the value of the business. Successful turn around and divestiture, Post Merger Integration, M&A transactions (buy, sell, JV) 15  
  16. 16.   Cheryl Richardson Launchpad Venture Group Cheryl Richardson is the New York Times bestselling author of several books including, Take Time for Your Life, Life Makeovers, Stand Up for Your Life, The Unmistakable Touch of Grace, The Art of Extreme Self Care and her new book with Louise Hay called You Can Create an Exceptional Life. She was the first president of the International Coach Federation and holds one of their first Master Certified Coach credentials. Her work has been covered widely in the media including Good Morning America, The Today Show, CBS This Morning, New York Times, USA Today, Good Housekeeping, and O Magazine. She was the team leader for the Lifestyle Makeover Series on the Oprah Winfrey Show and she accompanied Ms. Winfrey on the “Live Your Best Life” nationwide tour. Cheryl also served as the co-executive producer and host of “The Life Makeover Project with Cheryl Richardson” on the Oxygen Network and as the co-executive producer and host of two Public Television Specials – “Stand Up for Your Life” and “Create an Abundant Life.” You can check out Cheryl’s radio talk show — Coach on Call — on the Internet at www.hayhouseradio.com. The show airs live on Mondays at 5pm ET (2pm PT) and is replayed throughout the week. You can also find her Facebook Fan Page here and follow her on Twitter under her username “coachoncall.” Ed Ross is President and Managing Director of Excelerate Ventures LLC, a strategy and commercialization consultancy and angel investment cooperative focusing on disruptive medical innovation. Ed Ross President and Managing Director Excelerate Ventures LLC Mr. Ross has spearheaded the development and global commercialization of several significant disruptive medical device and regenerative technologies including InFuse, the current ‘gold standard’ bone-growth implant nearing $1 billion in sales through Medtronic. Recently Mr. Ross was the Vice President and General Manager for Alphatec Spine where he initiated an independent orthobiologics division and launched PureGen, a disruptive stem cell line for spinal reconstruction. Mr. Ross has been a founding and/or executive team member for notable medical device start-ups including ConforMIS, Gliatech, Anika Therapeutics and ClozeX Medical, a wound closure company acquired by 3M Healthcare. Prior to entrepreneurial pursuits, Mr. Ross built the orthopedic, anesthesia and healthcare IT businesses for industry leaders such as Zimmer, Genetics Institute, American Hospital Supply and Whittaker General Medical, all marked by successful introductions of key innovations. An active advisor and Board Member to several startups, Mr. Ross is a founding member of MDG, the Medical Development Group, and active in Mass Medical Angels and Golden Seeds. He serves on the steering committees of entrepreneurial educational groups including the MIT Enterprise Forum Life Sciences Group and the North Shore Technology Council. Mr. Ross has an MBA in Marketing and Finance from University of Rochester and a Bachelor of Arts in Political Science from Dickinson College. 16  
  17. 17.   Praveen Tailam Managing Director TiE Angels Boston @tieboston As a managing director Praveen overseas the operation of the TiE Angels functions and partnerships. Praveen is an active investor, mentor, start-up advisor, entrepreneur and business plan competition judge. Prior experience includes Information Technology and Consulting. Praveen incorporated Redtail Consulting, a Boston area consulting firm and managed the business from 2006 thru 2012. Praveen was associated with companies in retail, banking and insurance sectors and catering to their IT infrastructure needs. Prior to being an entrepreneur his direct engagements were in managing and deploying enterprise messaging solutions at IBM, Putnam Investments, Wellpoint, Blue Cross Blue Shield etc,. Additionally Praveen works closely with his dentist wife in managing multiple dental practices in New Hampshire area. Praveen has Masters in Information Systems from Northeastern University and Bachelors in Mechanical Engineering. Praveen is an avid golfer and has interests in cricket and squash. Praveen is active charter member of TiE-Boston. Mark Tepper President and CEO JB Therapeutics @marktepper Dr. Tepper has more than twenty years of leadership experience in pharmaceutical and biotech companies including Bristol Myers Squibb, Serono, CytRx, RXi Pharmaceuticals and NKT Therapeutics. He has been involved in the discovery, development, and approval of a number of marketed drugs including Deoxyspergualin, Taxol, Rebif, Orcenia and Gonal-F. He has successfully founded and led a number of therapeutics based biotech companies and raised over $45M in funding for these companies and provided investors with a high ROI. Dr. Tepper received a Ph.D. in Biochemistry & Biophysics from Columbia University, New York, and a B.A in Chemistry (Cum Laude) from Clark University, Worcester, Mass. He gained postdoctoral training at the University of Massachusetts Medical School, Worcester, MA in the laboratory of Professor Michael P. Czech. 17  
  18. 18.   Leslie Williams CEO ImmusanT @ImmusanT Leslie Williams has more than 20 years of industry experience in healthcare, management, commercial product development and marketing. Williams joined the specialty pharmaceutical company, Ventaira, in 2003 and was quickly promoted to president and chief executive officer from 2004 to 2007. Prior to Ventaira, Williams was director of marketing for INO Therapeutics, Inc., where she played a significant role in the development of INOmax (nitric oxide). Williams's prior pharmaceutical industry experience includes commercial positions at Merck and GlaxoSmithKline, and drug-delivery and monitoring experience at Datex-Ohmeda (formerly Ohmeda, Inc.) where she also discovered, developed and managed "OptimizOR". Leslie was a Venture Partner with Battelle Ventures, and serves on the Board of CDI Bioscience. She also serves on the board of Hepregen, an MIT spin out, which has developed a stable and highly functional micro- liver model. Leslie currently serves as Interim CEO for an early stage Cancer Therapeutics company in Cambridge, MA. Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree biology with honors in nursing from the University of Iowa. 18  
  19. 19.   Dr. Jill Wittels is CEO of Sostenuto Strategic Advisors and a Founding Partner and Chief Technology Officer of Terra Prima Partners LLC. She serves as Fiduciary or Advisory Director or Strategic Advisor to technology companies in a wide range of markets. Jill Wittels She is Chair of the Board of eMagin (EMAN), an OLED microdisplays company, since August 2011. - She is an Advisory Board Director for SmartSenseCom, an early stage company with equipment in field trials for better control of high and medium voltage transmission on the electric grid. - She was a founder and Strategic Advisor to Owl Biomedical, a medical device company spun out in December of 2010 and successfully sold to a strategic buyer in January 2013. - She has served on the Board of Directors of Fermi Research Alliance, which oversees the DOE’s Fermi National Accelerator Laboratory, since 1995, with a short break from June 2011-August 2013. - She serves as a CEO advisor to early stage companies in the New England high tech zone in markets from medical IT to mobile banking security Launchpad Venture Group Sostenuto Strategic Advisors Terram Prima Partners LLC @LaunchpadVG Since launching SSA in July of 2011, Dr. Wittels has also done consulting work for several of the top rank Aerospace and Defense enterprises. In July 2011 she retired as Corporate VP of Business and Technology Strategy at L-3 Communications, which she had joined in February 2001 to report to the CEO, Frank Lanza. During her tenure at L-3, Dr. Wittels had oversight responsibility for the Corporation’s $400M+ investment budget. She served for 10 years as a L-3’s Director of Innovative Microtechnologies Inc, a CA based MEMS company, as well as for 15 years as a Director on the Board of Overseers of DOE’s Fermi National Accelerator Laboratory in Batavia, IL. Dr. Wittels has nearly 35 years of business unit P&L management, strategy, engineering management and leadership experience. Prior to L3 Communications, Dr. Wittels worked for 21 years with BAE Systems and its predecessor companies, including Lockheed Martin, Loral and Honeywell. She was the instrumental leader in launching the thermal infrared microbolometer products business, which was the spark for creation of a multi-billion dollar industry supplying DoD, first responders, and commercial applications. In her final assignment with BAE, she served as VP/GM of BAE Systems' Information and Electronic Warfare Systems/Infrared and Imaging Systems Division. Dr. Wittels began her industrial career at Honeywell as a systems engineer. Prior to industry, Dr. Wittels served as a Congressional Fellow for the American Physical Society working in the US Senate, a Senior Visiting Scientist for the US National Academy of Sciences exchange program with the USSR Academy of Sciences and a Research Associate at the Massachusetts Institute of Technology. Dr. Wittels received a Bachelor of Science degree in Physics from MIT in 1970 and a PhD in Physics from MIT in 1975. She is a member of the National Association of Corporate Directors, the Corporate Directors Group, and Women Corporate Directors, as well as the 19   American Physical Society and the American Astronomical Society.
  20. 20.   20